1. Home
  2. ACAD vs DORM Comparison

ACAD vs DORM Comparison

Compare ACAD & DORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.80

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Dorman Products Inc.

DORM

Dorman Products Inc.

HOLD

Current Price

$112.94

Market Cap

4.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
DORM
Founded
1993
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.0B
IPO Year
2000
1996

Fundamental Metrics

Financial Performance
Metric
ACAD
DORM
Price
$21.80
$112.94
Analyst Decision
Buy
Strong Buy
Analyst Count
22
8
Target Price
$30.55
$160.25
AVG Volume (30 Days)
1.3M
185.7K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
69.12
8.14
EPS
2.30
6.64
Revenue
$726,437,000.00
$2,130,319,000.00
Revenue This Year
$18.80
$9.70
Revenue Next Year
$11.70
$4.92
P/E Ratio
$9.80
$17.01
Revenue Growth
40.45
6.03
52 Week Low
$14.45
$98.45
52 Week High
$28.35
$166.88

Technical Indicators

Market Signals
Indicator
ACAD
DORM
Relative Strength Index (RSI) 47.72 59.16
Support Level $21.51 $109.98
Resistance Level $22.03 $130.01
Average True Range (ATR) 0.61 3.13
MACD 0.04 0.59
Stochastic Oscillator 42.51 78.46

Price Performance

Historical Comparison
ACAD
DORM

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About DORM Dorman Products Inc.

Dorman Products Inc is a supplier of original equipment parts for automobiles. It offers automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, Super ATV, etc., through aftermarket retailers, warehouse distributors, specialty markets, and salvage yards. The company operates through three business segments, which include Light Duty, Heavy Duty, and Specialty Vehicle. A majority of its revenue is generated from the Light Duty segment, which designs and markets replacement parts and fasteners mainly for passenger cars and light trucks. Geographically, it derives key revenue from the United States.

Share on Social Networks: